One To Watch

Eli Lilly

A 150-year-old American pharmaceutical company that has become the world's most valuable healthcare company through its blockbuster incretin medicines for obesity and diabetes, while advancing broad pipelines in oncology, cardiovascular disease, immunology, and Alzheimer's disease.

Company Overview

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with a 150-year heritage of discovery and a current position as the world's most valuable pharmaceutical company by market capitalisation. In November 2025, Lilly became the first healthcare company to achieve a $1 trillion market capitalisation, driven primarily by the extraordinary commercial success of tirzepatide (Mounjaro for diabetes, Zepbound for obesity). The company operates in 18 countries and sells medicines in approximately 125 markets worldwide. Lilly's 2025 revenues surpassed expectations as Mounjaro and Zepbound generated multi-billion dollar sales, cementing Lilly's leadership in the cardiometabolic space and funding a dramatically expanded pipeline.

Headquarters and Global Presence

Eli Lilly's global headquarters are located in Indianapolis, Indiana, where the company has been based since its founding in 1876. The company has significant operations across North America, Europe, and Asia, with offices in 18 countries and commercial reach extending to approximately 125 markets. To support its rapidly expanding portfolio, Lilly announced investments of $55 billion in manufacturing infrastructure globally, encompassing 13 new facilities across active pharmaceutical ingredient, dry, parenteral, and device manufacturing networks expected to come online over the coming years. Key international hubs include operations in Ireland, Germany, Switzerland, Japan, and China.

Founding and History

Eli Lilly and Company was founded on 10 May 1876 by Colonel Eli Lilly, a Union Army veteran, pharmacist, and chemist, who opened a pharmaceutical manufacturing business in Indianapolis with just three employees including his son Josiah. The company's early successes included quinine for malaria and a number of medicinal preparations. During the 20th century, Lilly achieved landmark contributions to medicine, including the first commercial production of insulin in 1923 in collaboration with the University of Toronto, the development of Prozac (fluoxetine), and pioneering work in antibiotics and natural products. The acquisition of Loxo Oncology in 2019 for $8 billion fundamentally redirected the company toward precision oncology, and the approval of tirzepatide in 2022 launched Lilly into a new era of extraordinary commercial growth.

Therapy Areas and Focus

Lilly's primary therapeutic focus spans cardiometabolic health (diabetes, obesity, cardiovascular disease), oncology, immunology, and neuroscience. In cardiometabolic health, the company is the global leader in incretin-based therapies with tirzepatide and is pursuing next-generation agents including retatrutide (GIP/GLP-1/glucagon triple agonist) and eloralintide (amylin receptor agonist). In oncology, Lilly has rapidly built a portfolio through Loxo Oncology encompassing targeted therapies for lung and other cancers. In immunology, acquisitions of Ventyx Biosciences and Orna Therapeutics are broadening the portfolio. In neuroscience, donanemab and remternetug target Alzheimer's disease amyloid pathology, and Carole Ho's Lilly Neuroscience division coordinates a dedicated pipeline.

Technology Platforms and Modalities

Lilly's science spans small molecules, monoclonal antibodies, bispecific antibodies, RNA medicines, and novel genetic medicine platforms. In metabolic disease, the company has mastered peptide-based incretin pharmacology and is developing oral GLP-1 receptor agonists (orforglipron) that could radically expand access to obesity treatment. In cardiovascular disease, lepodisiran is an siRNA targeting lipoprotein(a) with sustained effects from a single injection. In Alzheimer's disease, donanemab and remternetug are anti-amyloid monoclonal antibodies. The $2.4 billion acquisition of Orna Therapeutics brings circular RNA (oRNA) technology for immunology and oncology. The $2.75 billion partnership with Insilico Medicine integrates artificial intelligence drug discovery into Lilly's pipeline.

Key Pipeline and Programs

Retatrutide, Lilly's triple agonist (GIP/GLP-1/glucagon receptor), demonstrated up to 29% weight loss and met primary endpoints in Phase 3 diabetology trials reported in March 2026, positioning it as a potential best-in-class obesity therapy. Orforglipron, an oral GLP-1 receptor agonist, is in Phase 3 maintenance trials. Donanemab received FDA approval for Alzheimer's disease. Remternetug, a self-administered anti-amyloid antibody, is in the Phase 3 TRAILRUNNER-ALZ-1 trial. Lepodisiran is in the Phase 3 ACCLAIM-Lp(a) cardiovascular outcomes trial following 94% Lp(a) reduction in Phase 2. Four oncology medicines are in Phase 3 trials. The pipeline includes over 34 discovery programmes across incretins, amylins, and novel metabolic targets.

Key Personnel

David A. Ricks serves as Chairman and Chief Executive Officer, having held the role since 2017, and has led the company through its transformation into the world's most valuable pharmaceutical enterprise. Daniel M. Skovronsky, M.D., Ph.D., serves as Executive Vice President, Chief Scientific and Medical Officer, and President of Lilly Research Laboratories. Jacob Van Naarden leads as Executive Vice President and President of Lilly Oncology, with responsibility for corporate business development; he spearheaded the Loxo Oncology acquisition strategy. Carole Ho, M.D., serves as Executive Vice President and President, Lilly Neuroscience. Kenneth Custer, Ph.D., leads Lilly Cardiometabolic Health. Ilya Yuffa oversees Lilly USA and global commercial capabilities.

Strategic Partnerships

Lilly's most significant 2026 strategic moves include a $2.75 billion deal with Insilico Medicine for AI-developed drugs (signed March 2026), the $2.4 billion acquisition of Orna Therapeutics for circular RNA medicines in immunology and oncology, a $1.2 billion acquisition agreement for Ventyx Biosciences to advance oral therapies for inflammatory diseases, and an $8.5 billion strategic collaboration with Innovent Biologics for oncology and immunology programmes giving Lilly global rights outside Greater China. A $1.2 billion research collaboration with Nimbus Therapeutics targets oral obesity treatments. Earlier, the 2019 acquisition of Loxo Oncology for $8 billion has proven transformative for the oncology portfolio, and the partnership with Boehringer Ingelheim in cardiometabolic disease has been a long-standing commercial collaboration.

FAQ Section

Lilly's central strategic challenge is sustaining and expanding its dominant market position in obesity and diabetes therapeutics against intensifying competition from Novo Nordisk and emerging challengers, while simultaneously ensuring its manufacturing capacity expansion keeps pace with extraordinary and rapidly growing global demand for its incretin medicines.

Triple receptor agonism with retatrutide adds glucagon receptor engagement to the dual GIP/GLP-1 mechanism of tirzepatide, potentially driving greater metabolic rate increase and weight loss than dual agonists, with Phase 3 data from March 2026 demonstrating up to 29% weight reduction and significant glycaemic improvement in type 2 diabetes.

Lilly differentiates itself through an unrivalled depth of incretin science spanning injectable peptides, oral small molecules, and next-generation amylin receptor targets, combined with a rapidly assembled precision oncology capability through Loxo Oncology and frontier RNA and genetic medicine platforms being brought in through aggressive business development.

Lepodisiran demonstrated up to 94% reduction in lipoprotein(a) levels with effects lasting more than a year from a single injection in Phase 2 data, which would make it potentially the most potent and durable Lp(a)-lowering therapy in development and a compelling option for the large high-cardiovascular-risk population with elevated Lp(a).

Lilly's pipeline is defined by cardiometabolic innovation across obesity, diabetes, and cardiovascular disease, precision oncology through targeted therapies, Alzheimer's disease amyloid-directed therapy, immunology through oral and RNA-based approaches, and emerging genetic medicine via circular RNA, with more than 75% of new programmes outside incretins and amylins.

Eli Lilly is the world's most commercially dynamic pharmaceutical company, generating blockbuster revenues from tirzepatide while rapidly scaling manufacturing and executing a multi-billion dollar business development strategy to ensure continued growth across oncology, immunology, cardiovascular disease, and neuroscience as its obesity franchise matures.

Key watchpoints include Phase 3 completion and regulatory submissions for retatrutide in obesity and diabetes, the ACCLAIM-Lp(a) cardiovascular outcomes trial for lepodisiran, the TRAILRUNNER-ALZ-1 Phase 3 data for remternetug in Alzheimer's disease, progress of the Orna Therapeutics circular RNA platform, and the speed at which Lilly's manufacturing investments can unlock supply for growing global demand.

Want to Update your Company's Profile?